Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. - Wikidata - wikimedia - TriplyDB

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

http://www.wikidata.org/entity/Q33265192

about

Using endoscopy to minimize the extent of resection in the management of giant GISTs of the stomach.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.A rare case of primary mesenteric gastrointestinal stromal tumor with metastasis to the cervix uteri.Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.Surgical treatment of gastric gastrointestinal stromal tumor Duodenal GIST: a single center experience Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib.Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.Reintroduction of imatinib in GIST Imatinib treatment for gastrointestinal stromal tumour (GIST).Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Adjuvant therapy of gastrointestinal stromal tumors (GIST).The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation.Selective RNAi-mediated inhibition of mutated c-kit.Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy.Massive intra-abdominal imatinib-resistant gastrointestinal stromal tumor in a 21-year-old male.Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec).Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour.Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum.Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors.Giant gastrointestinal stromal tumor of the vermiform appendix: A case report.MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.Management of hemorrhage in gastrointestinal stromal tumors: a review.The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.

P2860

Q33716121-C499B223-8FF4-45C6-9684-532F5E78CD65 Q34050275-9FA38233-4C28-4C2D-8604-2A4C8D0201C7 Q34202396-005E0DA1-0680-428A-9564-345D96937601 Q34497045-0B1A7FFA-5F96-44C0-A890-3573BB400660 Q35111851-CDAE1626-933D-48DE-B977-C6FCDA7B3D2E Q35676187-27F9CBAA-C759-4575-97A8-869DC4C74607 Q35791389-0CB2BF9D-9D39-4B97-A404-0C2B153E2BA1 Q36417321-A246AB27-5FA6-4FF8-BA6D-6A71DF869AD6 Q36499861-3ED5119A-BF27-415C-A375-D7E1D29B65DB Q36563238-D2009AD8-E531-448D-BE5F-004907E89C36 Q36770203-F8DC830F-F46D-452D-A714-58D8CB6BBFFC Q36803986-56AE8559-3CFD-4A73-AAE8-1C44DAA28239 Q37023177-96320696-7D83-44CB-9E90-486199717309 Q37131713-3F918101-1876-4EAF-9A8E-AD52E1A56D63 Q37161655-0C7FCDCB-9E5A-4DDB-B452-419FC90A9C56 Q37301364-45D6BF89-3D65-404E-A02C-2C753F565165 Q37334993-8330E515-9656-4158-BC39-F6269EDBD134 Q37405941-6E0E8C64-3B8D-47E1-B4D7-413F5876AC26 Q37747750-5F25CEB5-2D0B-4F62-974C-2FF67E37C1A1 Q37823438-6CA2939F-C8AA-44C3-9E01-9F282E0AB99E Q38022443-18CEE3A6-A393-49EB-948B-9B19AC172F51 Q38714790-A178045F-3B3A-407F-9EEA-63B73830BEF9 Q38829078-9EBA6E70-6647-4F9E-A51E-BC9145FCF5F2 Q41836202-0ED4004C-B052-4F24-A0EC-161FD574DFD9 Q42134185-13DDC00C-6DEA-4482-8ADA-042CFEB30F39 Q42560774-669C77F1-364B-498E-AB53-1EB120C0A2A9 Q43100127-0F8C2429-A8FA-4B60-B4D6-CC8343A60A22 Q43730826-285EF97B-CCC4-4631-A201-579DCFE1C39A Q43903971-DB500A7D-CC33-4EBD-BFFA-8213A81BB320 Q44700932-B1811D77-2CF7-4280-8C64-6F1DC2EC0976 Q46114032-C619CA73-3425-4F0C-A151-A6AF28748959 Q49237178-D3B152FE-41B3-44E4-AA4E-D6294A662C2C Q50144404-F792838E-529D-497F-857B-26BF1AED953A Q50469164-B170F71D-7619-48BC-949A-724D17211339 Q50913835-B1C7E95A-A4A1-42F8-BF3C-7B2BE5B65B2A Q52562706-28A98531-20BD-4081-8CF9-A4CF62F90030 Q54539960-E0CBD779-6CB6-4D5D-9ECC-79B21B9B50DD Q55059101-9CB2A7EC-8E74-4691-8411-13A001D98685

P2860

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

http://www.wikidata.org/entity/Q33265192

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Surgical management after neoa ...... ed by secondary KIT mutations.

@ast

Surgical management after neoa ...... ed by secondary KIT mutations.

@en

type

label

Surgical management after neoa ...... ed by secondary KIT mutations.

@ast

Surgical management after neoa ...... ed by secondary KIT mutations.

@en

prefLabel

Surgical management after neoa ...... ed by secondary KIT mutations.

@ast

Surgical management after neoa ...... ed by secondary KIT mutations.

@en

P1433

Q33265192-CC6A5031-11C8-4973-80EF-4399F0C91401

P1476

Q33265192-E8D1C054-8DF0-4CCA-B3C2-DEBD91E2590B

P2093

Q33265192-022D96FB-18AC-45B0-BB89-2C3D6C842516

Q33265192-20560A70-0026-4DF0-9F6E-FEF2FDC76C87

Q33265192-32969363-F343-4805-8C34-07BEE7E849D3

Q33265192-62E1CD0E-1DDD-453E-8ADB-3E5E219DAF16

Q33265192-65AAFA2B-63D2-4AED-9128-26770B9BC311

Q33265192-76F64277-643C-4810-B36F-00F3045C8684

Q33265192-EF14F508-304B-4EF3-9B57-AA9D5D151B6C

P2888

Q33265192-C21B9913-98B7-493E-807C-148D26A21D1E

P304

Q33265192-B4DE623C-8BF6-4A93-82C4-BFB31B53B492

P31

Q33265192-DDF7B896-458C-43C3-BA73-25F86F32D622

P356

Q33265192-416BCDC0-71A6-4F6F-A593-93306347BB24

P433

Q33265192-7517FF63-1117-4AD9-986B-AED29D8FB4F0

P478

Q33265192-B3086AD9-9BAE-4134-B73E-E546B7A53C28

P577

Q33265192-9B723F69-D3CF-4513-B871-16170AD8BFB5

P6179

Q33265192-90DB8AF0-AEAC-48AC-B8F2-477AD5BA16DF

P698

Q33265192-448B4845-644F-4654-BAC9-8DB331A4F7D4

P356

S10434-006-9228-0

P1433

Annals of Surgical Oncology

P1476

Surgical management after neoa ...... ed by secondary KIT mutations.

@en

P2093

Bastian Gunawan

http://www.w3.org/2001/XMLSchema#string

Florian Haller

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Schulten

http://www.w3.org/2001/XMLSchema#string

Jens Kuhlgatz

http://www.w3.org/2001/XMLSchema#string

László Füzesi

http://www.w3.org/2001/XMLSchema#string

Nicole Happel

http://www.w3.org/2001/XMLSchema#string

Sven Detken

http://www.w3.org/2001/XMLSchema#string

P2888

s10434-006-9228-0

P304

526-532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-006-9228-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024470042

http://www.w3.org/2001/XMLSchema#string

P698

17139461

http://www.w3.org/2001/XMLSchema#string